Vaš brskalnik ne omogoča JavaScript!
JavaScript je nujen za pravilno delovanje teh spletnih strani. Omogočite JavaScript ali pa uporabite sodobnejši brskalnik.
Nacionalni portal odprte znanosti
Odprta znanost
DiKUL
slv
|
eng
Iskanje
Brskanje
Novo v RUL
Kaj je RUL
V številkah
Pomoč
Prijava
Meta-analysis and experimental validation identified FREM2 and SPRY1 as new glioblastoma marker candidates
ID
Vidak, Marko
(
Avtor
),
ID
Jovchevska, Ivana
(
Avtor
),
ID
Šamec, Neja
(
Avtor
),
ID
Zottel, Alja
(
Avtor
),
ID
Liović, Mirjana
(
Avtor
),
ID
Rozman, Damjana
(
Avtor
),
ID
Džeroski, Sašo
(
Avtor
),
ID
Juvan, Peter
(
Avtor
),
ID
Komel, Radovan
(
Avtor
)
PDF - Predstavitvena datoteka,
prenos
(9,34 MB)
MD5: 83FE430F48BFB92CCC15C1E10F308C74
URL - Izvorni URL, za dostop obiščite
http://www.mdpi.com/1422-0067/19/5/1369
Galerija slik
Izvleček
Glioblastoma (GB) is the most aggressive brain malignancy. Although some potential glioblastoma biomarkers have already been identified, there is a lack of cell membrane-bound biomarkers capable of distinguishing brain tissue from glioblastoma and/or glioblastoma stem cells (GSC), which are responsible for the rapid post-operative tumor reoccurrence. In order to find new GB/GSC marker candidates that would be cell surface proteins (CSP), we have performed meta-analysis of genome-scale mRNA expression data from three data repositories (GEO, ArrayExpress and GLIOMASdb). The search yielded ten appropriate datasets, and three (GSE4290/GDS1962, GSE23806/GDS3885, and GLIOMASdb) were used for selection of new GB/GSC marker candidates, while the other seven (GSE4412/GDS1975, GSE4412/GDS1976, E-GEOD-52009, E-GEOD-68848, E-GEOD-16011, E-GEOD-4536, and E-GEOD-74571) were used for bioinformatic validation. The selection identified four new CSP-encoding candidate genes-CD276, FREM2, SPRY1, and SLC47A1-and the bioinformatic validation confirmed these findings. A review of the literature revealed that CD276 is not a novel candidate, while SLC47A1 had lower validation test scores than the other new candidates and was therefore not considered for experimental validation. This validation revealed that the expression of FREM2-but not SPRY1-is higher in glioblastoma cell lines when compared to non-malignant astrocytes. In addition, FREM2 gene and protein expression levels are higher in GB stem-like cell lines than in conventional glioblastoma cell lines. FREM2 is thus proposed as a novel GB biomarker and a putative biomarker of glioblastoma stem cells. Both FREM2 and SPRY1 are expressed on the surface of the GB cells, while SPRY1 alone was found overexpressed in the cytosol of non-malignant astrocytes.
Jezik:
Angleški jezik
Ključne besede:
glioblastoma
,
glioblastoma stem cells
,
biomarkers
,
data repositories
,
meta-analysis
,
cell surface
,
experimental validation
,
FREM2
,
SPRY1
Vrsta gradiva:
Članek v reviji
Tipologija:
1.01 - Izvirni znanstveni članek
Organizacija:
MF - Medicinska fakulteta
Status publikacije:
Objavljeno
Različica publikacije:
Objavljena publikacija
Leto izida:
2018
Št. strani:
24 str.
Številčenje:
Vol. 19, iss. 5, art. 1369
PID:
20.500.12556/RUL-131851
UDK:
577
ISSN pri članku:
1422-0067
DOI:
10.3390/ijms19051369
COBISS.SI-ID:
33752793
Datum objave v RUL:
04.10.2021
Število ogledov:
1139
Število prenosov:
191
Metapodatki:
Citiraj gradivo
Navadno besedilo
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Kopiraj citat
Objavi na:
Gradivo je del revije
Naslov:
International journal of molecular sciences
Skrajšan naslov:
Int. j. mol. sci.
Založnik:
MDPI
ISSN:
1422-0067
COBISS.SI-ID:
2779162
Licence
Licenca:
CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:
http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:
To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:
04.05.2018
Sekundarni jezik
Jezik:
Slovenski jezik
Ključne besede:
glioblastom
,
matične celice glioblastoma
,
biomarkerji
Projekti
Financer:
Drugi - Drug financer ali več financerjev
Program financ.:
Junior Researcher grant
Številka projekta:
1240-1/2013-123-2
Financer:
ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:
P1-0390
Naslov:
Funkcijska genomika in biotehnologija za zdravje
Financer:
ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:
P2-0103
Naslov:
Tehnologije znanja
Financer:
EC - European Commission
Program financ.:
Interreg
Akronim:
TRANS-GLIOMA
Podobna dela
Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:
Nazaj